Af­ter hit­ting big in mul­ti­ple myelo­ma, J&J, Gen­mab now have a new 'break­through' in NSCLC to boast about

Lend­ing cre­dence to J&J and Gen­mab’s promise that their al­liance can pro­duce some­thing big out­side of mul­ti­ple myelo­ma, the FDA has grant­ed break­through ther­a­py des­ig­na­tion for JNJ-6372 — a bis­pe­cif­ic against metasta­t­ic non-small cell lung can­cer.

The ear­ly-stage drug hits EGFR (epi­der­mal growth fac­tor re­cep­tor) and MET (mes­enchy­mal ep­ithe­lial tran­si­tion fac­tor) mu­ta­tions and am­pli­fi­ca­tions. Specif­i­cal­ly, an ap­proval could make it the first tar­get­ed ther­a­py for pa­tients who have EGFR ex­on 20 in­ser­tion mu­ta­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.